Barclays PLC Boosts Stock Position in OPKO Health, Inc. (NASDAQ:OPK)

Barclays PLC grew its position in OPKO Health, Inc. (NASDAQ:OPK) by 154.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 543,336 shares of the biotechnology company’s stock after buying an additional 329,870 shares during the quarter. Barclays PLC owned 0.08% of OPKO Health worth $810,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in OPK. Rubric Capital Management LP lifted its holdings in shares of OPKO Health by 800.0% in the 2nd quarter. Rubric Capital Management LP now owns 44,422,304 shares of the biotechnology company’s stock worth $55,528,000 after buying an additional 39,486,490 shares during the period. Assenagon Asset Management S.A. lifted its stake in shares of OPKO Health by 142.5% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after purchasing an additional 876,272 shares during the last quarter. Clearline Capital LP purchased a new stake in shares of OPKO Health during the 3rd quarter worth $1,083,000. Squarepoint Ops LLC purchased a new stake in shares of OPKO Health during the 2nd quarter worth $592,000. Finally, Exchange Traded Concepts LLC lifted its stake in shares of OPKO Health by 135.7% during the 3rd quarter. Exchange Traded Concepts LLC now owns 387,108 shares of the biotechnology company’s stock worth $577,000 after purchasing an additional 222,869 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

OPK has been the subject of a number of analyst reports. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, January 8th. Finally, Barrington Research restated an “outperform” rating and set a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost purchased 100,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 14th. The shares were purchased at an average cost of $1.62 per share, with a total value of $162,000.00. Following the purchase, the chief executive officer now owns 211,612,405 shares of the company’s stock, valued at $342,812,096.10. This represents a 0.05 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders have purchased 1,804,255 shares of company stock valued at $2,764,605. Company insiders own 47.26% of the company’s stock.

OPKO Health Trading Down 0.7 %

Shares of NASDAQ:OPK opened at $1.47 on Thursday. The business’s 50-day moving average is $1.54 and its 200 day moving average is $1.50. OPKO Health, Inc. has a 1 year low of $0.86 and a 1 year high of $1.76. The firm has a market capitalization of $1.00 billion, a P/E ratio of -7.74 and a beta of 1.62. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.